Enterprise Value
190.5M
Cash
871.6M
Avg Qtr Burn
-64.74M
Short % of Float
22.21%
Insider Ownership
2.42%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RLY-4008 (FGFR2 inhibitor) Details Solid tumor/s, Intrahepatic cholangiocarcinoma | Phase 1/2 Data readout | |
RLY-2608 (PI3Kα inhibitor) Details Breast cancer | Phase 1 Data readout | |
GDC-1971 (RLY-1971) Details Solid tumor/s | Failed Discontinued |